Southeast Asia's Only Co-Located Vaccine & Biologics Congress
14 - 15 October 2026
Sheraton Grand Jakarta Gandaria City Hotel, Indonesia
Sponsors & Media Partners
Special thanks to our event partners, without whom we would not be able to provide this networking, learning, and collaborating platform.
GOLD
Bronze
Exhibitors
%20(1)%20(1).png)
Associate
%202.png)
2026 SPEAKERS
Badarulhisam Abdul Rahman, PhD
Chief Scientific Officer
Pharmaniaga Berhad
Malaysia
Zainab Sadat
General Manager, Vaccines, Southeast Asia & India MCO
Sanofi
Singapore
Meenu Batolar
Global Regulatory Affairs Asia Pacific Lead
CEPI
Singapore
Dr. Neni Nurainy
Head of Translational Development of Life Science Product
Bio Farma
Indonesia
M. Indra Lamora
Director – Anti Infectious Department
Etana Biotechnologies
Indonesia
Indriana Permatasari
Project Manager
International Vaccine Institute (IVI)
Indonesia
Dr. Soleh Ayubi
Chief of Country Representative
PATH
Indonesia
Dr. Jetsumon Sattabongkot Prachumsri
Director, Mahidol Vivax Research Unit
Mahidol University
Thailand
Dr. Indra Rudiansyah
Project Lead, mRNA Vaccine Programme
Bio Farma
Indonesia
Dr. Wenshuo Zhou
Senior Director R&D & CEO Scientific Assistant
Abogen Biosciences
China
Prasen Adya
Deputy Director
Serum Institute of India
India
Dr. Nicholas Lim
Medical Head, RSV Vaccines India & Southeast Asia MCO
Sanofi
Singapore
Dr. Seyed Reza Banihashemi
Director of R&D
Razi Vaccine & Serum Research Institute
Iran
Xiaoyuan Zhao
International Clinical Project Management Expert, R&D Division
CanSino Biologics Inc.
Switzerland
Mr. Mohd Fadhil bin Razmi
Head of Cluster, Vaccine & Logistics, Malaysia Vaccine Project Office (MVPO)
Ministry of Science, Technology & Innovation (MOSTI)
Malaysia
Claire Chong
Technical application manager
Tofflon Science and Technology Group Co., Ltd.
Singapore
Sophie Lam
Regional Business Manager
BD Southeast Asia Biopharma System
Singapore
Yuli Fitriyani Syoemantri
Head of BCG Vaccine Production Department
Bio Farma
Indonesia
Dr. Martina Ochs
Programme Leader - RNA Programme
CEPI
United Kingdom
Dr. Mrunal Shetye
Chief of Health
UNICEF Indonesia Country Office
Abhijit Kayal
Senior Scientist II
Schrodinger
India
Sophie Lam
Regional Business Manager
BD Southeast Asia Biopharma System
Singapore
Bobby George
Senior Vice President, Head Regulatory Affairs
Reliance Life Sciences
India
Butet Manurung
Managing Director
Jakarta Biopharmaceutical Industry (JBio)
Indonesia
Cheng Yi (Jerry) Kuo
Vice General Manager
UWELL Biopharma
Taiwan
Chethan A J
Assistant Director - QA & RA, Center for Ocular Regeneration (CORE)
Brien Holden Eye Research Center (BHERC)
India
Christian Karol Saputra
Head of Corporate Relation & Strategic Affair
Etana Biotechnologies
Indonesia
Deepak Mukherjee
Country Medical Director
Roche
Indonesia
Doo Young Jung
Chief Executive Officer
PinotBio
South Korea
Kurt Wee
Chief Executive Officer
Celligenics
Singapore
Lutfhi Zarkasyi
Director of Manufacturing
Kalbio Global Medika
Indonesia
Nicolas Husser
Head of Operations
Kalbio Global Medika
Indonesia
Rakhmat Budi Yuwono
Quality Director
Etana Biotechnologies
Indonesia
Dr. Seyed Reza Banihashemi
Director of R&D
Razi Vaccine & Serum Research Institute
Iran
Sandy Qlintang
President Director
Bifarma Adiluhung
Indonesia
Shanti Marlina Sibuea
Acting Director of Production Control of Drugs, Narcotics, Psychotropics, and Precursors
Indonesian National Agency of Drug and Food Control (Badan POM/BPOM)
Indonesia
Syifa Mutiara Hersista
Digital Tech Research Manager
Bio Farma
Indonesia
Vaibhav Dubey
Senior General Manager
Sun Pharmaceuticals
India
Vipul Doshi
Chief Quality and Compliance Officer
Zydus Lifesciences
India
Yagna Praveen
Asst Vice President, Head of Strategic Research
Pharmaniaga
Malaysia
Agenda At A Glance
CONFERENCE DAY 1 | 14th October 2026 |
CONFERENCE DAY 2 | 15th October 2026 |
|||
.png)
|
|
|
|
|
|
Opening Plenary
Building Southeast Asia’s Biologics & Vaccine Ecosystem
|
mRNA, Viral Vector & Novel Platforms for Fast-Response Vaccines
|
Bioprocessing & Manufacturing Innovation in Southeast Asia
|
||
| Morning Tea, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking | ||||
|
Next-Generation Vaccine Discovery & Platform Technologies
|
Therapeutic Biologics Market Growth & Commercial Opportunities in Southeast Asia
|
Vaccine Showcase
Emerging & Re-Emerging Infectious Diseases in Southeast Asia
|
CDMO, Technology Transfer & Manufacturing Partnerships in Asia
|
|
| Lunch, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking | ||||
|
Clinical Trials & Regulatory Harmonization in SEA
|
R&D, Clinical Development & Translational Science for Biologics
|
Vaccine Distribution & Cold Chain
|
Future Modalities
Next-Generation Cell & Advanced Biologics
|
|
| Afternoon Tea, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking | ||||
|
Scaling Biomanufacturing Capacity & Technology Transfer Across SEA
|
Clinical Adoption, Reimbursement & Market Access for Therapeutic Biologics
|
Leadership Panel
Can Southeast Asia Become a Global Biomanufacturing Powerhouse?
|
||
| End of Conference | ||||
CONFERENCE DAY 1 | 14th October 2026 | |
|
|
|
|
Opening Plenary
Building Southeast Asia’s Biologics & Vaccine Ecosystem
|
|
| Morning Tea, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking | |
|
Next-Generation Vaccine Discovery & Platform Technologies
|
Therapeutic Biologics Market Growth & Commercial Opportunities in Southeast Asia
|
| Lunch, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking | |
|
Clinical Trials & Regulatory Harmonization in SEA
|
R&D, Clinical Development & Translational Science for Biologics
|
| Afternoon Tea, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking | |
|
Scaling Biomanufacturing Capacity & Technology Transfer Across SEA
|
Clinical Adoption, Reimbursement & Market Access for Therapeutic Biologics
|
| End of Conference | |
CONFERENCE DAY 2 | 15th October 2026 | |
|
|
|
|
mRNA, Viral Vector & Novel Platforms for Fast-Response Vaccines
|
Bioprocessing & Manufacturing Innovation in Southeast Asia
|
| Morning Tea, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking | |
|
Vaccine Showcase
Emerging & Re-Emerging Infectious Diseases in Southeast Asia
|
CDMO, Technology Transfer & Manufacturing Partnerships in Asia
|
| Lunch, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking | |
|
Vaccine Distribution & Cold Chain
|
Future Modalities
Next-Generation Cell & Advanced Biologics
|
| Afternoon Tea, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking | |
|
Leadership Panel
Can Southeast Asia Become a Global Biomanufacturing Powerhouse?
|
|
| End of Conference | |
CONFERENCE AGENDA
Day 1
14 October 2026
Vaccine World Asia Congress 2026
Biologics World Asia Congress 2026
8:50
IMAPAC Opening Remarks
8:55
Chairman Opening Remarks
Butet Manurung
Managing Director, Jakarta Biopharmaceutical Industry (JBio)
.png)
Opening Plenary: Building Southeast Asia’s Biologics & Vaccine Ecosystem
9:00
Panel Discussion: Building a Resilient Biologics & Vaccine Ecosystem in Southeast Asia: From Capacity to Capability
- Bridging gaps across R&D, manufacturing, and supply chain to create a connected regional ecosystem
- Public-private partnerships: Aligning governments, industry, and academia to accelerate innovation
- Strengthening regional self-sufficiency vs. global dependency in vaccine and biologics production
- Talent, infrastructure, and policy: What’s needed to position Southeast Asia as a global hub
MODERATOR
Dr. Mrunal Shetye
Chief of Health, UNICEF Indonesia Country Office
PANELISTS
Dr. Soleh Ayubi
Chief of Country Representative, PATH
Prasen Adya
Deputy Director, Serum Institute of India
Mr. Mohd Fadhil bin Razmi
Head of Cluster, Vaccine & Logistics, Malaysia Vaccine Project Office (MVPO), Ministry of Science, Technology & Innovation (MOSTI)
Meenu Batolar
Global Regulatory Affairs Asia Pacific Lead, CEPI
9:50
Accelerating the 100 Days Mission: Leveraging Platform Evidence and Innovative Safety Frameworks for Rapid Vaccine Development
- Harnessing platform technologies to accelerate vaccine development through the strategic use of prior CMC, non-clinical, and clinical data.
- Advancing regulatory preparedness by enabling reliance on platform knowledge, standardized approaches, and outbreak-responsive regulatory pathways
- Implementing risk-based safety frameworks that support Emergency Use Listing (EUL) while maintaining robust benefit-risk oversight
- Building evidence at the pace of pandemics through platform-specific safety surveillance, standardized AESI definitions, and real-world data generation
Meenu Batolar
Global Regulatory Affairs Asia Pacific Lead, CEPI
10:15
Morning Tea Break, Exhibition Viewing & 1-1 Attendee Networking
Next-Generation Vaccine Discovery & Platform Technologies
SESSION CHAIR
Prasen Adya
Deputy Director, Serum Institute of India
Therapeutic Biologics Market Growth & Commercial Opportunities in Southeast Asia
11:00
From Pathogen to Platform: Accelerating Vaccine Discovery in the Post-Pandemic Era
- What are the advantages of the RNA modality in infectious disease development and broader therapeutic areas?
- How can we achieve deep optimization of RNA technologies?
- In which potential areas might RNA technology outperform other modalities?
Dr. Wenshuo Zhou
Senior Director R&D & CEO Scientific Assistant, Abogen Biosciences
11:00
Accelerating Biologics Innovation in Indonesia: From Research to Market Access
- Identifying gaps in the drug development process and potential solutions
- Exploring the end-to-end biologics development pipeline, from upstream research through commercialization and market access
- Examining the role of pentahelix collaboration in accelerating biologics innovation
Christian Karol Saputra
Head of Corporate Relation & Strategic Affair, Etana Biotechnologies
11:25
V2P – New generation Vaccines Delivery Solutions
- Vaccine packaging trends and future-ready delivery solutions
- Benefits of converting from Vial to prefilled for vaccine safety and efficiency
- Innovations in vaccine administration and immunization access
- How BD's integrated service and solution can support pharma companies for sustainable approaches to vaccine delivery and deployment
Sophie Lam
Regional Business Manager, BD Southeast Asia Biopharma System
11:25
Building Regional Biomanufacturing Capacity: From Infrastructure & Operations to Manufacturing Scale-Up (TBC)
Reserved for Nicolas Husser
Head of Operations, Kalbio Global Medika
11:50
Strategic Framework for Designing ADCs with a Better Therapeutic Window
- Building a quantitative model to explain discrepancies between the preclinical and clinical therapeutic windows of Top1i payload ADCs
- Applying insights from the quantitative model to design new payloads for ADCs with an improved therapeutic window
- Expanding the application of quantitative models to enable the development of next-generation ADCs
Doo Young Jung
Chief Executive Officer, PinotBio
11:50
Lunch, Exhibition Viewing & 1-1 Attendees Networking
12:15
Lunch, Exhibition Viewing & 1-1 Attendees Networking
Clinical Trials & Regulatory Harmonization in SEA
R&D, Clinical Development & Translational Science for Biologics
1:30
The Future of Needle-Free Immunization: Advances in Intranasal and Mucosal Vaccines
- Advancing intranasal and mucosal vaccine platforms as alternatives to traditional injectable vaccines
- Understanding the potential of mucosal immunity for preventing infection and transmission
- Addressing R&D, clinical, regulatory, and manufacturing challenges in developing needle-free vaccines
- Exploring opportunities to improve vaccine accessibility, acceptance, and rapid deployment through next-generation delivery approaches
Dr. Seyed Reza Banihashemi
Director of R&D, Razi Vaccine & Serum Research Institute
1:40
Clinical Development & Translational Science for Advanced Biologics
- Stages of translational science and the clinical development pathway
- Why advanced biologics translate differently: addressing the translation gap through quality by design (qbd)
- Key risks in clinical development & translational research: how translational teams can mitigate them
Chethan A J
Assistant Director - QA & RA, Center for Ocular Regeneration (CORE), Brien Holden Eye Research Center (BHERC)
1:55
Navigating Clinical Trials in Indonesia: Insights and Partnerships for Chinese and Local Stakeholders
- Practical experiences and lessons learned from conducting Phase 1/2 infants’ polio vaccine trials in Indonesia.
- Key regulatory and operational considerations for non-Indonesian sponsors entering the Indonesian market.
- Bridging expectations: Understanding specific requirements from China to streamline cross-border collaborations.
Xiaoyuan Zhao
International Clinical Project Management Expert, R&D Division, CanSino Biologics Inc.
2:05
Accelerating Biologics R&D: A Strategic Roadmap for Computational Engineering
- Navigating Multi-Parameter Optimization Trade-Offs: Biologics design requires balancing multiple properties, as optimizing target affinity can compromise critical attributes such as protein stability and selectivity
- Real-World Computational Case Studies: Demonstrating the application of physics-based modelling to large-scale mutagenesis, cross-reactivity screening, multi-parameter ideation, and addressing developability challenges
- Reducing Experimental Cycles and Development Risk: Predicting protein stability and binding energy to support candidate selection, minimize laboratory iterations, and accelerate the development of therapeutic biologics
Abhijit Kayal
Senior Scientist II, Schrodinger
2:20
Speed vs. Compliance: Balancing Agility and Regulatory Rigor in Clinical Development
- Maintaining data integrity while accelerating trial timelines
- Risk-based approaches to regulatory review and monitoring
- Adaptive trial designs and their regulatory acceptance in Asia
- Managing variability in country-specific regulatory expectations
Indriana Permatasari
Project Manager, International Vaccine Institute (IVI)
2:20
Reinventing the Quality Function: From Quality Assurance to Quality Intelligence
- Using AI to automate repetitive quality tasks and investigations
- Moving from periodic audits and inspection to predictive and continuous assurance
- Leveraging AI driven quality metrics to support faster, smarter decision making
Vipul Doshi
Chief Quality and Compliance Officer, Zydus Lifesciences
2:45
Afternoon Tea Break, Exhibition Viewing & 1-1 Attendee Networking
2:45
Afternoon Tea Break, Exhibition Viewing & 1-1 Attendee Networking
Scaling Biomanufacturing Capacity & Technology Transfer Across SEA
Clinical Adoption, Reimbursement & Market Access for Therapeutic Biologics
3:40
From Technology Transfer to Flexible Manufacturing: Building Scalable Vaccine Capacity in Southeast Asia
- Translating technology transfer into clear manufacturing, process and GMP requirements
- Designing for scale and flexibility, with modular manufacturing concepts and single-use technologies as key enablers
- Building future-ready manufacturing capacity that can adapt to different vaccine platforms, production volumes and evolving regional demand
Claire Chong
Technical application manager, Tofflon Science and Technology Group Co., Ltd.
3:30
Generating Actionable Evidence: Medical Affairs as the Architect of Value in Biologics Access
- Addressing financial & access barriers to biologics in southeast asia
- Generating evidence to accelerate post launch access
- Building a unified medical affairs evidence strategy
Deepak Mukherjee
Country Medical Director, Roche
4:05
Winning the race to the market: The blueprint for flawless tech transfer
- Technical complexity and knowhow
- Hard and soft infrastructure
- Operational challenges
- Regulatory bottlenecks
Badarulhisam Abdul Rahman, PhD
Chief Scientific Officer, Pharmaniaga Berhad
3:55
Fireside Chat: From Development to Adoption: Advancing Access to Innovative Biologics
- What are the key challenges in translating innovative biologics from clinical development into real-world clinical practice?
- How can clinical evidence, quality, and regulatory strategies better support clinical adoption and patient access?
- What can industry, healthcare providers, and policymakers do to build sustainable pathways for innovative biologics across Southeast Asia?
MODERATOR
Chethan A J
Assistant Director - QA & RA, Center for Ocular Regeneration (CORE), Brien Holden Eye Research Center (BHERC)
PANELISTS
Deepak Mukherjee
Country Medical Director, Roche
4:30
Tech Transfer: Vaccines Accessibility and Affordability
- Accelerating technology transfer to strengthen local and regional vaccine manufacturing capacity
- Overcoming technical, regulatory and knowledge-transfer barriers to enable faster scale-up
- Reducing manufacturing costs to improve vaccine affordability and accessibility
- Building sustainable partnerships between vaccine developers, manufacturers and governments
Prasen Adya
Deputy Director, Serum Institute of India
4:25
Building Sustainable Market Access Pathways for Innovative Biologics in Asia (TBC)
Reserved for Vaibhav Dubey
Senior General Manager, Sun Pharmaceuticals
4:55
Chairman Closing Remarks
Prasen Adya
Deputy Director, Serum Institute of India
4:50
Chairman Closing Remarks
Butet Manurung
Managing Director, Jakarta Biopharmaceutical Industry (JBio)
5:00
End of Conference - Day 1
4:55
End of Conference - Day 1
CONFERENCE AGENDA
Day 2
15 October 2026
8:50
IMAPAC Opening Remarks
8:55
Chairman Opening Remarks
Indriana Permatasari
Project Manager, International Vaccine Institute (IVI)
8:55
Chairman Opening Remarks
Syifa Mutiara Hersista
Digital Tech Research Manager, Bio Farma
mRNA, Viral Vector & Novel Platforms for Fast-Response Vaccines
Bioprocessing & Manufacturing Innovation in Southeast Asia
9:00
mRNA Portfolios After COVID: From Breakthrough Breakthroughs to Sustainable Vaccine Platforms
- How mRNA developers are transitioning from emergency-use success to scalable, multi-indication vaccine pipelines
- Advancing mRNA applications across infectious diseases, oncology, and personalized vaccines
- Comparing strengths, limitations, and hybrid strategies for rapid-response vaccine development
- Building resilient, cost-effective mRNA production and supply chains for global deployment
Dr. Indra Rudiansyah
Project Lead, mRNA Vaccine Programme, Bio Farma
9:00
Strengthening Regulatory Oversight & GMP Readiness for Advanced Biologics Manufacturing in Asia
- Key regulatory challenges and opportunities in biologics manufacturing
- Enhancing GMP readiness and inspection capabilities for advanced modalities
- Lessons learned from regional regulatory convergence and PIC/S activities
- Strategies to strengthen manufacturing quality, compliance, and continuous improvement
Shanti Marlina Sibuea
Acting Director of Production Control of Drugs, Narcotics, Psychotropics, and Precursors, Indonesian National Agency of Drug and Food Control (Badan POM/BPOM)
9:25
Advancing Indonesia’s Dengue Vaccine Innovation: Lessons from the Development of a Tetravalent mRNA Dengue Vaccine Prototype
- The journey behind developing Indonesia’s tetravalent mRNA dengue vaccine prototype
- How academia, industry and government collaboration can accelerate homegrown vaccine R&D
- Opportunities and challenges in applying mRNA technology to dengue vaccine development
- Translating local vaccine innovation into clinical development, regulatory pathways and future access
M. Indra Lamora
Director – Anti Infectious Department, Etana Biotechnologies
9:25
Driving Acceleration in Insulin and GLP-1 Projects
- GLP-1 and biologics market trends shaping injectable drug delivery
- Patient-centric delivery solutions for self-injection
- De-risking and accelerating combination product development
- BD’s technical, testing and regulatory support from concept to market
Sophie Lam
Regional Business Manager, BD Southeast Asia Biopharma System
9:50
Panel Discussion: Fast-Response Vaccines: Are Platform Technologies Ready for the Next Pandemic?
- Comparing speed, scalability, and flexibility of mRNA vs viral vectors
- Key bottlenecks in rapid design-to-deployment timelines
- Lessons from COVID-19: what worked, what didn’t
- Building platform readiness for future outbreak scenarios
MODERATOR
Badarulhisam Abdul Rahman, PhD
Chief Scientific Officer, Pharmaniaga Berhad
PANELISTS
Dr. Indra Rudiansyah
Project Lead, mRNA Vaccine Programme, Bio Farma
M. Indra Lamora
Director – Anti Infectious Department, Etana Biotechnologies
Dr. Seyed Reza Banihashemi
Director of R&D, Razi Vaccine & Serum Research Institute
Dr. Martina Ochs
Programme Leader - RNA Programme, CEPI 
9:40
AI for Biologics Innovation: From Intelligent Vaccine Design to Data-Driven Manufacturing
- AI Opportunities in Biologics Innovation
- Scaling AI from R&D to Manufacturing
- Overcoming Data, Validation & Regulatory Challenges
Syifa Mutiara Hersista
Digital Tech Research Manager, Bio Farma
10:05
Bioprocessing & Manufacturing Innovation in Southeast Asia
- Shift to Advanced Biologics and Vaccines: Transitioning from traditional generic drug manufacturing to high-value therapeutics, including monoclonal antibodies, biosimilars, and mRNA vaccine platforms
- Geographical Specialization and Stratification: Positioning regional markets as specialized R&D and CDMO hubs, leveraging strong institutional frameworks, abundant biomass, and large domestic markets to advance precision fermentation and vaccine self-sufficiency
- Adoption of Next-Generation Modular Technologies: Overcoming infrastructure limitations through flexible single-use bioreactors, continuous processing, and AI-driven process analytical technology (PAT) to achieve cost-effective manufacturing while maintaining international quality and compliance standards
Butet Manurung
Managing Director, Jakarta Biopharmaceutical Industry (JBio)
10:40
Morning Tea Break, Exhibition Viewing & 1-1 Attendee Networking
10:30
Morning Tea Break, Exhibition Viewing & 1-1 Attendee Networking
Vaccine Showcase: Emerging & Re-Emerging Infectious Diseases in South East Asia
CDMO & Technology Transfer Partnerships in Southeast Asia
11:20
RSV Prevention in Infants: Translating Clinical Evidence into Population-Level Protection
- Latest clinical and real-world evidence on RSV disease burden and vaccine effectiveness in infants and young children
- Understanding the impact of RSV prevention on hospitalizations, healthcare utilization, and long-term pediatric outcomes
- Identifying high-risk populations and strategies to maximize protection during the first years of life
- Translating evidence into national immunization policies and sustainable pediatric vaccination programs
Dr. Nicholas Lim
Medical Head, RSV Vaccines India & Southeast Asia MCO, Sanofi
11:10
Building End-to-End CDMO Capabilities in Southeast Asia: From Tech Transfer to Commercial Supply
- Scaling from clinical to commercial manufacturing within regional CDMOs
- Infrastructure readiness: single-use systems, modular facilities, digitalization
- Ensuring consistency and comparability across sites
- Case studies of successful end-to-end CDMO partnerships
Lutfhi Zarkasyi
Director of Manufacturing, Kalbio Global Medika
11:45
Advancing Plasmodium vivax Vaccine R&D: Addressing an Emerging Infectious Disease Challenge in Southeast Asia
- Understanding the evolving P. vivax burden and its significance across Southeast Asia
- Addressing the scientific challenges of developing vaccines against P. vivax, including its complex life cycle
- Exploring innovative vaccine platforms, antigens and approaches to achieve durable protection
- Accelerating P. vivax vaccine candidates from research and clinical development toward regional access
Dr. Jetsumon Sattabongkot Prachumsri
Director, Mahidol Vivax Research Unit, Mahidol University
11:35
Accelerating GMP Readiness in SEA: Infrastructure, Quality Systems, and Compliance
- Establishing GMP-compliant facilities aligned with global regulatory standards
- Building QA/QC systems and inspection readiness (FDA, EMA, PIC/S)
- Workforce training and capability development for biologics manufacturing
- Common pitfalls in facility qualification and validation
Rakhmat Budi Yuwono
Quality Director, Etana Biotechnologies
12:00
Regulatory Updates on the Biologics Product Licensing Pathway in India
- Updates to the similar biologics' guidelines
- Digital transformation drive at CDSCO
- Legislative reforms on the horizon
Bobby George
Senior Vice President, Head Regulatory Affairs, Reliance Life Sciences
12:25
Lunch, Exhibition Viewing & 1-1 Attendees Networking
12:25
Lunch, Exhibition Viewing & 1-1 Attendees Networking
Vaccine Distribution & Cold Chain
SESSION CHAIR
Dr. Jetsumon Sattabongkot Prachumsri
Director, Mahidol Vivax Research Unit, Mahidol University
Future Modalities: Next-Generation Cell & Advanced Biologics
1:40
Scaling Vaccine Manufacturing in Southeast Asia: Strengthening Capacity, Digitalisation & Supply Reliability
- Scaling manufacturing capacity while maintaining GMP and product quality
- BCG vaccine manufacturing as a case study in managing biological complexity and process robustness
- Digitalisation and eBR to strengthen data integrity, process control and manufacturing efficiency
- Building reliable and resilient vaccine supply through operational excellence and technology transfer
Yuli Fitriyani Syoemantri
Head of BCG Vaccine Production Department, Bio Farma
1:40
Clinical Development of CAR-T Cell Therapy: Manufacturing, Formulation, Administration & Quality Control
- Key Considerations for CAR-T Cell Therapy Development
- Overview of the CAR-T Cell Manufacturing Process
- Phase I Clinical Trial of UWC19 in R/R B-NHL
Cheng Yi (Jerry) Kuo
Vice General Manager, UWELL Biopharma
2:05
Beyond Approval: Scaling Awareness, Access, and Sustainable Uptake of New Vaccines
- Improving public awareness and vaccine confidence
- Expanding access through innovative funding and reimbursement models
- Addressing affordability and health equity challenges
- Strengthening stakeholder collaboration to drive adoption
- Ensuring long-term sustainability of vaccination programs
Zainab Sadat
General Manager, Vaccines, Southeast Asia & India MCO, Sanofi
2:05
Applications of Regenerative Secretome Technology & Peptides in Functional Health
- Next-generation stem cell technology: cell-free, scalable, and cost-effective approaches
- The shift towards personalised early intervention
- Targeted applications in medical wellness
Kurt Wee
Chief Executive Officer, Celligenics
2:30
Reducing Vaccine Wastage: Inventory Management and Demand Forecasting in Cold Chain Systems
- Improving demand planning and stock allocation accuracy
- First-expiry-first-out (FEFO) and inventory tracking systems
- Minimizing overstocking and stockouts across regions
- Role of analytics and AI in supply chain optimization
Dr. Soleh Ayubi
Chief of Country Representative, PATH
2:30
The UCMSC Secretome: A Cell-Free Hydrogel for Tissue Regeneration in Chronic Wounds
- Dual Bioactivity: Anti-inflammatory and anti-fibrotic effects of the UCMSC secretome through macrophage polarization and reduction of TGF-β-induced α-SMA expression
- Clinical Efficacy: Evaluation of secretome hydrogel in chronic wound healing, including complete epithelialization within 5 days in a 64 cm² wound
- Advantages of Cell-Free Therapy: An off-the-shelf, serum- and antibiotic-free formulation with an 18-month shelf life, offering potential advantages in safety, scalability and regulatory development compared with live-cell therapies
Sandy Qlintang
President Director, Bifarma Adiluhung
2:55
Advancing Immunology, Innovation & Bioprocessing for Future Vaccines (TBC)
Reserved for Dr. Seyed Reza Banihashemi
Director of R&D, Razi Vaccine & Serum Research Institute
2:55
Afternoon Tea Break, Exhibition Viewing & 1-1 Attendee Networking
3:20
Afternoon Tea Break, Exhibition Viewing & 1-1 Attendee Networking
Leadership Panel: Can Southeast Asia Become a Global Biomanufacturing Powerhouse?
4:00
Leadership Panel: Can Southeast Asia Become a Global Vaccine & Biomanufacturing Powerhouse?
- What will it take for Southeast Asia to become a leading hub for vaccine and biologics manufacturing?
- How can governments and industry accelerate investments in talent, infrastructure, and advanced manufacturing capabilities?
- What role can regional collaboration play in strengthening supply chain resilience and reducing reliance on imports?
MODERATOR
Shanti Marlina Sibuea
Acting Director of Production Control of Drugs, Narcotics, Psychotropics, and Precursors, Indonesian National Agency of Drug and Food Control (Badan POM/BPOM)
PANELISTS
Dr. Neni Nurainy
Head of Translational Development of Life Science Product, Bio Farma
Butet Manurung
Managing Director, Jakarta Biopharmaceutical Industry (JBio)
4:40
Enabling Next-Generation Biologics Manufacturing in Southeast Asia Through Innovation & Strategic Partnerships (TBC)
Reserved for Yagna Praveen
Asst Vice President, Head of Strategic Research, Pharmaniaga
5:05
Chairman Closing Remarks
Syifa Mutiara Hersista
Digital Tech Research Manager, Bio Farma
5:10
End of Conference
By Profile
By Job Title
By Geography
35%
Singapore, Thailand, Malaysia, Laos & Vietnam
25%
Indonesia
25%
China, Taiwan, Korea & Japan
10%
Australia, India & Hong Kong
5%
USA & Europe
35%
Singapore, Thailand, Malaysia, Laos & Vietnam
25%
Indonesia
25%
China, Taiwan, Korea & Japan
10%
Australia, India & Hong Kong
5%
USA & Europe
Our Past Partners
%20(1)%20(1)%20(1).png){kind=logo}
.jpg)
PARTNER WITH US
Sponsorship Packages
Tailored sponsorship opportunities designed to maximize your brand visibility and lead generation.
Platinum Sponsor
Speaking & thought leadership
- 1 Conference presentation: 20 min (+ 5 min live Q&A). In the main conference sessions.
- 1 End-user client case study: 20 min (+ 5 min live Q&A). Complimentary, in the main conference sessions.
- 1 Pre-conference workshop: Half day (catered for 30 pax). Room hire and one refreshment included. Limited to 1 - 2 sponsors.
- 1 Conference chairmanship: Day 2. Optional and subject to availability.
- 1 Pre-event speaker interview. Shared with the Vaccine & Biologics community and on social media.
Exhibition
- 1 Exhibition space: 12 sqm (6 × 2 m table-top, upgrade to 18 sqm). In the Exhibition Hall. All upgrades are complimentary.
Passes & networking
- 1 Speaker pass. Premium conference sessions and the Exhibition Hall.
- 7 Conference passes. Premium conference sessions and the Exhibition Hall.
- 2 Exhibitor passes. To staff the booth.
- 5 1:1 meeting assistance. Help setting up meetings on site with targeted companies.
Branding & reach
- 1 Logo placement: Priority. Official brochure front page (sent to 20,000+ targeted senior executives), event web page with a two-way link, every event ad in media partners' publications and IMAPAC's marketing including social media, and the backdrop, on-site signage and event banners.
- 1 Corporate profile online: 200 words. Maximum length, on the official event web page.
- 1 Brochure distribution. At the registration desk or conference table.
- 1 Corporate gift distribution. Optional.
- 1 In-depth post-event report. Exclusive to sponsors.
Gold Sponsor
Speaking & thought leadership
- 1 Conference presentation: 20 min (+ 5 min live Q&A). In the main conference sessions.
- 1 Panel or roundtable moderator. Complimentary.
- 1 Pre-event speaker interview. Shared with the Vaccine & Biologics community and on social media.
Exhibition
- 1 Exhibition space: 9 sqm (4.5 × 2 m table-top, upgrade to 12 sqm). In the Exhibition Hall. All upgrades are complimentary.
Passes & networking
- 1 Speaker pass. Premium conference sessions and the Exhibition Hall.
- 6 Conference passes. Premium conference sessions and the Exhibition Hall.
- 2 Exhibitor passes. To staff the booth.
- 5 1:1 meeting assistance. Help setting up meetings on site with targeted companies.
Branding & reach
- 1 Logo placement: Priority. Official brochure front page (sent to 20,000+ targeted senior executives), event web page with a two-way link, every event ad in media partners' publications and IMAPAC's marketing including social media, and the backdrop, on-site signage and event banners.
- 1 Corporate profile online: 150 words. Maximum length, on the official event web page.
- 1 Brochure distribution. At the registration desk or conference table.
- 1 Corporate gift distribution. Optional.
- 1 In-depth post-event report. Exclusive to sponsors.
Silver Sponsor (Enhanced)
Speaking & thought leadership
- 1 Conference presentation: 25 min (with live Q&A). In the main conference sessions.
Exhibition
- 1 Exhibition space: 6 sqm (3 × 2 m table-top, upgrade to 9 sqm booth). In the Exhibition Hall. All upgrades are complimentary.
Passes & networking
- 1 Speaker pass. Premium conference sessions and the Exhibition Hall.
- 4 Conference passes. Premium conference sessions and the Exhibition Hall.
- 2 Exhibitor passes. To staff the booth.
Branding & reach
- 1 Logo placement: Standard. Official brochure front page (sent to 20,000+ targeted senior executives), event web page with a two-way link, every event ad in media partners' publications and IMAPAC's marketing including social media, and the backdrop, on-site signage and event banners. Credited as Silver Sponsor.
- 1 Corporate profile online: 100 words. Maximum length, on the official event web page.
- 1 In-depth post-event report. Exclusive to sponsors.
Silver Sponsor
Speaking & thought leadership
- 1 Conference presentation: 15 min (with live Q&A). In the main conference sessions.
Exhibition
- 1 Exhibition space: 6 sqm (3 × 2 m table-top). In the Exhibition Hall. All upgrades are complimentary.
Passes & networking
- 1 Speaker pass. Premium conference sessions and the Exhibition Hall.
- 3 Conference passes. Premium conference sessions and the Exhibition Hall.
- 2 Exhibitor passes. To staff the booth.
Branding & reach
- 1 Logo placement: Standard. Official brochure front page (sent to 20,000+ targeted senior executives), event web page with a two-way link, every event ad in media partners' publications and IMAPAC's marketing including social media, and the backdrop, on-site signage and event banners.
- 1 Corporate profile online: 100 words. Maximum length, on the official event web page.
- 1 In-depth post-event report. Exclusive to sponsors.
Bronze Sponsor
Speaking & thought leadership
- 1 Conference presentation: 15 min (with live Q&A). In the main conference sessions.
Exhibition
- 1 Exhibition space: 1 sqm (upgrade to 6 sqm for first-time clients). In the Exhibition Hall. All upgrades are complimentary. Space for a banner display and/or a small networking table. The upgrade, to a 3 × 2 m table-top, is a one-time offer.
Passes & networking
- 1 Speaker pass. Premium conference sessions and the Exhibition Hall.
- 1 Conference passes. Premium conference sessions and the Exhibition Hall.
Branding & reach
- 1 Logo placement: Standard. Official brochure front page (sent to 20,000+ targeted senior executives), event web page with a two-way link, every event ad in media partners' publications and IMAPAC's marketing including social media, and the backdrop, on-site signage and event banners.
- 1 Corporate profile online: 100 words. Maximum length, on the official event web page.
- 1 In-depth post-event report. Exclusive to sponsors.
Exhibitor
Exhibition
- 1 Exhibition space: 6 sqm (3 × 2 m table-top). In the Exhibition Hall. All upgrades are complimentary.
Passes & networking
- 2 Conference passes. Premium conference sessions and the Exhibition Hall.
- 2 Exhibitor passes. To staff the booth.
Branding & reach
- 1 Logo placement: Standard. Official brochure front page (sent to 20,000+ targeted senior executives), event web page with a two-way link, every event ad in media partners' publications and IMAPAC's marketing including social media, and the backdrop, on-site signage and event banners.
- 1 Promotional video: 1 - 2 min. Played in the ad slots across both event days.
- 1 Corporate profile online: 100 words. Maximum length, on the official event web page.
- 1 In-depth post-event report. Exclusive to sponsors.
Which event would you like to sponsor?
The two congresses run side by side in Jakarta. Choose the one you would like to enquire about or get in touch about both.
Selected package:
Be a Part of This Event!
Don't miss out on unique networking, speaking and sponsorship opportunities.